The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...
2025 has plenty to offer in the health sphere – and Australians are at the forefront of treatments
He knows the drug works but said there were challenges in getting TGA approval. Self-injectable medications such as ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly blockbuster drugs ...
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...
The US FDA has approved the anti-diabetic drug Zepbound (Tirzepatide) for managing obstructive sleep apnea (OSA) in obese ...
Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help ...
Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback